CAMP4 Therapeutics (NASDAQ:CAMP) held its 2026 annual meeting of stockholders in a virtual format, with shareholders approving all three matters put to a vote, including the election of directors, ratification of the company’s auditor and an amendment to its equity incentive plan.
Josh Mandel-Brehm, president, chief executive officer and director of CAMP4 Therapeutics, presided over the meeting at the direction of the chair of the board. He said the company designed the virtual meeting to provide stockholders “the same rights and opportunities to participate as they would in an in-person meeting.”
Quorum Established
Mandel-Brehm said Broadridge Financial Solutions had certified that the notice of the annual meeting and proxy statement were sent to all stockholders of record as of April 13, 2026.
According to the meeting transcript, holders of 51,925,800 shares of common stock were entitled to vote. The inspector of election reported that 39,998,634 shares of common stock were represented at the meeting, either virtually or by proxy, equal to approximately 77% of all shares entitled to vote. Mandel-Brehm declared that a quorum existed.
Stockholders Approve Three Proposals
Stockholders voted on three proposals at the annual meeting:
- The election of three Class II directors to serve until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified.
- The ratification of the appointment of Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.
- The approval of an amendment to the CAMP4 Therapeutics Corporation 2024 Equity Incentive Plan.
The three director nominees were Steven Holtzman, Murray Stewart and Richard Young. Mandel-Brehm said that, based on the preliminary voting report, each nominee had been elected as a Class II director.
He also said stockholders ratified Ernst & Young LLP as the company’s independent registered public accounting firm and approved the amendment to the company’s 2024 Equity Incentive Plan.
Final Results to Be Filed
Mandel-Brehm said the final vote results will be included in a Form 8-K to be filed within four business days after the meeting.
The company provided an opportunity for stockholders to submit questions through the virtual meeting platform. Mandel-Brehm noted that questions on personal matters or general economic, political or other views not directly related to the company’s business or matters before the meeting would not be answered. No questions were raised during the formal proposal portion, according to the transcript.
After announcing the preliminary voting results and stating that there was no further business to come before the meeting, Mandel-Brehm adjourned the formal portion of the annual meeting.
About CAMP4 Therapeutics (NASDAQ:CAMP)
CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.
